Dose proportionality and pharmacokinetics of fentanyl buccal soluble film in healthy subjects: A phase I, open-label, three-period, crossover study

Clinical Drug Investigation

Volumn 32, Issue 1, 2012, Pages 63-71

  Finn, Andrew L ^a   Vasisht, Niraj ^a   Stark, Jeffrey G ^b   Gever, Larry N ^c   Tagarro, Ignacio ^c,d  

^a BioDelivery Sciences International Inc   (United States)

^b Worldwide Clinical Trials Drug Development Solutions   (United States)

^c Meda Pharmaceuticals Inc   (United States)

^d Meda Pharma SAU   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ADHESIVE AGENT; FENTANYL; NALTREXONE; NARCOTIC ANALGESIC AGENT;

ADULT; APPLICATION SITE ERYTHEMA; ARTICLE; CHEEK MUCOSA; CROSSOVER PROCEDURE; DISEASE SEVERITY; DIZZINESS; DOSE RESPONSE; DRUG DELIVERY SYSTEM; DRUG DOSE COMPARISON; DRUG WITHDRAWAL; FEMALE; GASTROINTESTINAL SYMPTOM; HUMAN; HUMAN EXPERIMENT; MALE; NAUSEA; NORMAL HUMAN; OPEN STUDY; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; SINGLE DRUG DOSE; ADOLESCENT; AREA UNDER THE CURVE; CHEEK; CLINICAL TRIAL; MOUTH MUCOSA; YOUNG ADULT;

ADOLESCENT; ADULT; ANALGESICS, OPIOID; AREA UNDER CURVE; CHEEK; CROSS-OVER STUDIES; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; FENTANYL; HUMANS; SOLUBILITY; HEALTHY VOLUNTEERS; MOUTH MUCOSA; YOUNG ADULT;

EID: 82555194576     PISSN: 11732563     EISSN: 11791918     Source Type: Journal    
DOI: 10.2165/11594670-000000000-00000     Document Type: Article

References (18)

1. Gutstein H, Akil H. Opioid analgesics. In: Hardman J, Limbird L, editors. Goodman and Gilmans the pharmacological basis of therapeutics. 10th ed. Maidenhead: McGraw-Hill: 2001: 569-619
2. Hanks GW, Nugent M, Higgs CM, et al. Oral transmucosal fentanyl citrate in the management of breakthrough pain in cancer: an open, multicentre, dose-titration and long-term use study. Palliat Med 2004 Dec; 18 (8): 698-704 (Pubitemid 39654548)
3. Feierman DE, Lasker JM. Metabolism of fentanyl, a synthetic opioid analgesic, by human liver microsomes: role of CYP3A4. Drug Metab Dispos 1996 Sep; 24 (9): 932-9 (Pubitemid 26314543)
4. Portenoy RK, Hagen NA. Breakthrough pain: definition, prevalence and characteristics. Pain 1990 Jun; 41 (3): 273-81 (Pubitemid 20187930)
5. Inturrisi CE. Clinical pharmacology of opioids for pain. Clin J Pain 2002 Jul-Aug; 18 (4 Suppl.): S3-13
6. Coluzzi PH, Schwartzberg L, Conroy JD, et al. Breakthrough cancer pain: a randomized trial comparing oral transmucosal fentanyl citrate (OTFC) and morphine sulfate immediate release (MSIR). Pain 2001 Mar; 91 (1-2): 123-30 (Pubitemid 32274181)
7. Portenoy RK, Payne R, Coluzzi P, et al. Oral transmucosal fentanyl citrate (OTFC) for the treatment of breakthrough pain in cancer patients: a controlled dose titration study. Pain 1999 Feb; 79 (2-3): 303-12 (Pubitemid 29076765)
8. Farrar JT, Cleary J, Rauck R, et al. Oral transmucosal fentanyl citrate: randomized, double-blinded, placebocontrolled trial for treatment of breakthrough pain in cancer patients. J Natl Cancer Inst 1998 Apr 15; 90 (8): 611-6 (Pubitemid 28204805)
9. Slatkin NE, Xie F, Messina J, et al. Fentanyl buccal tablet for relief of breakthrough pain in opioid-tolerant patients with cancer-related chronic pain. J Support Oncol 2007 Jul- Aug; 5 (7): 327-34 (Pubitemid 350055013)
10. Portenoy RK, Taylor D, Messina J, et al. A randomized, placebo-controlled study of fentanyl buccal tablet for breakthrough pain in opioid-treated patients with cancer. Clin J Pain 2006 Nov-Dec; 22 (9): 805-11 (Pubitemid 44627444)
11. Rauck R, North J, Gever LN, et al. Fentanyl buccal soluble film (FBSF) for breakthrough pain in patients with cancer: a randomized, double-blind, placebo-controlled study. Ann Oncol 2010 Jun; 21 (6): 1308-14
12. Streisand JB, Varvel JR, Stanski DR, et al. Absorption and bioavailability of oral transmucosal fentanyl citrate. Anesthesiology 1991 Aug; 75 (2): 223-9
13. Vasisht N, Gever LN, Tagarro I, et al. Evaluation of the single- and multiple-dose pharmacokinetics of fentanyl buccal soluble film in normal healthy volunteers. J Clin Pharmacol 2010 Jul; 50 (7): 785-91
14. Onsolis (fentanyl buccal soluble film). Prescribing information. Meda Inc. 2009
15. Vasisht N, Gever LN, Tagarro I, et al. Formulation selection and pharmacokinetic comparison of fentanyl buccal soluble film with oral transmucosal fentanyl citrate: a randomized, open-label, single-dose, crossover study. Clin Drug Investig 2009; 29 (10): 647-54
16. Gordon D, Schroeder M. Oral transmucosal fentanyl citrate: OTFC (ACTIQ) #103. J PalliatMed 2008 May; 11 (4): 633-4 (Pubitemid 351630207)
17. Gever L, Wheeler W, Hill W. Fentanyl absorption from fentanyl buccal soluble film (FBSF) in the presence of mucositis. Poster session presented at: PAINWeek - TheNationalConference on Pain for Frontline Practitioners; 2010 Sep 8-11; Las Vegas (NV)
18. Slatkin N, Hill W, Finn A. The safety of fentanyl buccal soluble film (FBSF) use for breakthrough (BTP) pain in cancer patients. Poster session presented at: 26th Annual Meeting of the American Academy of Pain Medicine (AAPM); 2010 Feb 3-6; San Antonio (TX).